A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir

What Was Tested

The paper reports a study of Insulin Detemir and NPH Insulin (isophane), published as a randomized controlled trial.

Who Took Part

According to the abstract, 12 patients were involved.

PubMed indexes the participants as teenagers and adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and crossover.

The patients were allocated by chance, so the Insulin Detemir group and the comparison group should start out alike.

As a double-blind Insulin Detemir study, the assignments were hidden from both participants and investigators until the end.

In the crossover set-up each of the patients took both Insulin Detemir and the comparison in turn, acting as their own control.

What Was Measured

The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 1, Fatty Acids, Nonesterified, Glucose, Glucose Clamp Technique, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Detemir and NPH Insulin (isophane) in 12 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2005 (Diabetes care), a journal based in United States.

More context: the Insulin Detemir compound page and the NPH Insulin (isophane) compound page, all human trials.